Combined Checkpoint Inhibition and Chemotherapy: New Era of 1
PD-1
PD-L1
checkpoint blockade
chemotherapy
combination therapy
immunotherapy
non-small cell lung cancer
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
28 Jun 2019
28 Jun 2019
Historique:
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
13
4
2019
Statut:
epublish
Résumé
Platinum-based chemotherapy has long been the first-line treatment of choice for metastatic non-small-cell lung cancer (NSCLC) patients who lack targetable gene mutations. The arrival of checkpoint blockade has led to a vast shift in the treatment landscape of NSCLC. Among NSCLC patients with PD-L1 expression in ≥50% of tumor cells, treatment with pembrolizumab leads to a superior progression-free and overall survival compared to platinum-doublet chemotherapy in the first-line setting. Furthermore, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significant longer progression-free survival and overall survival irrespective to PD-L1 expression. In this review, we focus on the molecular rationale for the combination therapy and the results of completed clinical studies.
Identifiants
pubmed: 30976658
doi: 10.1016/j.omto.2019.02.001
pii: S2372-7705(19)30009-9
pmc: PMC6444295
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1-6Références
J Immunol. 2004 Apr 1;172(7):4599-608
pubmed: 15034078
Int J Cancer. 2005 Nov 1;117(2):294-9
pubmed: 15900604
Clin Cancer Res. 2005 Sep 15;11(18):6713-21
pubmed: 16166452
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Clin Cancer Res. 2008 May 15;14(10):3185-92
pubmed: 18483387
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
Lung Cancer. 2009 May;64(2):194-8
pubmed: 18809226
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
Br J Cancer. 2010 Jan 5;102(1):115-23
pubmed: 19997099
J Clin Invest. 2010 Apr;120(4):1111-24
pubmed: 20234093
Cancer Metastasis Rev. 2011 Mar;30(1):61-9
pubmed: 21249425
J Clin Invest. 2011 Aug;121(8):3100-8
pubmed: 21765211
J Clin Oncol. 2012 Jun 10;30(17):2046-54
pubmed: 22547592
Curr Oncol. 2012 Jun;19(Suppl 1):S52-8
pubmed: 22787411
Ann Oncol. 2013 Jan;24(1):75-83
pubmed: 22858559
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Immunity. 2013 Jul 25;39(1):74-88
pubmed: 23890065
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Lancet. 2016 Apr 9;387(10027):1540-50
pubmed: 26712084
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
J Clin Oncol. 2016 Sep 1;34(25):2969-79
pubmed: 27354481
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Front Med (Lausanne). 2017 Jan 23;4:4
pubmed: 28168189
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Oncoimmunology. 2017 Jun 16;6(7):e1331807
pubmed: 28811975
Clin Cancer Res. 2018 Jan 15;24(2):407-419
pubmed: 29074606
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Eur J Cancer. 2018 Sep;101:114-122
pubmed: 30053670
J Thorac Oncol. 2019 Jan;14(1):124-129
pubmed: 30138764
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635